Will the 'true' factor level make itself known? Measuring factor therapy for treatment of hemophilia in the era of enhanced half-life products.
作者信息
Jenkins Peter V
机构信息
Department of Haematology University Hospital of Wales Cardiff Wales UK.
Department of Medicine Cardiff University Cardiff Wales UK.
出版信息
Res Pract Thromb Haemost. 2019 Jan 31;3(2):158-160. doi: 10.1002/rth2.12185. eCollection 2019 Apr.
Abstract
摘要
相似文献
1
Will the 'true' factor level make itself known? Measuring factor therapy for treatment of hemophilia in the era of enhanced half-life products.“真正的”因子水平会自行显现吗？在半衰期延长产品时代测量因子疗法治疗血友病的情况。
Res Pract Thromb Haemost. 2019 Jan 31;3(2):158-160. doi: 10.1002/rth2.12185. eCollection 2019 Apr.
2
Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients.延长半衰期凝血因子：血友病患者管理的新时代。
Turk J Haematol. 2019 Aug 2;36(3):141-154. doi: 10.4274/tjh.galenos.2019.2018.0393. Epub 2019 May 15.
3
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products.延长半衰期的凝血因子VIII/凝血因子IX产品时代的血友病预防
Semin Thromb Hemost. 2016 Jul;42(5):518-25. doi: 10.1055/s-0036-1571315. Epub 2016 Apr 20.
4
An update of the current pharmacotherapeutic armamentarium for hemophilia A.血友病 A 的当前药物治疗武器库的更新。
Expert Opin Pharmacother. 2022 Jan;23(1):129-138. doi: 10.1080/14656566.2021.1961742. Epub 2021 Aug 18.
5
Current and emerging factor VIII replacement products for hemophilia A.用于A型血友病的现有及新型凝血因子VIII替代产品。
Ther Adv Hematol. 2017 Oct;8(10):303-313. doi: 10.1177/2040620717721458. Epub 2017 Aug 26.
6
[New therapeutic directions on hemophilia].[血友病的新治疗方向]
Rinsho Ketsueki. 2019;60(9):1275-1282. doi: 10.11406/rinketsu.60.1275.
7
Immunogenicity of Current and New Therapies for Hemophilia A.目前及新型血友病A疗法的免疫原性
Pharmaceuticals (Basel). 2022 Jul 23;15(8):911. doi: 10.3390/ph15080911.
8
The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.延长半衰期与常规因子产品对血友病照顾者负担的影响。
Qual Life Res. 2018 May;27(5):1335-1345. doi: 10.1007/s11136-018-1792-9. Epub 2018 Feb 1.
9
Current and Future Options of Haemophilia A Treatments.当前和未来的血友病 A 治疗选择。
Expert Opin Biol Ther. 2021 Nov;21(11):1395-1402. doi: 10.1080/14712598.2021.1908993. Epub 2021 Apr 1.
10
The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States.延长半衰期因子浓缩物对美国重度血友病预防的影响。
Am J Hematol. 2020 Aug;95(8):960-965. doi: 10.1002/ajh.25844.
本文引用的文献
1
Reagent-specific underestimation of turoctocog alfa pegol (N8-GP) clotting activity owing to decelerated activation by thrombin.由于凝血酶激活减速导致的特定试剂对聚乙二醇化重组人凝血因子VIII（N8-GP）凝血活性的低估。
Res Pract Thromb Haemost. 2018 Dec 7;3(1):114-120. doi: 10.1002/rth2.12167. eCollection 2019 Jan.
2
International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.在临床止血实验室的血浆样本中评估 AFSTYLA 分析性能的国际比较现场研究。
J Thromb Haemost. 2018 Mar;16(3):555-564. doi: 10.1111/jth.13932. Epub 2018 Feb 1.
3
Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.使用市售的一步凝血法和发色底物法检测试剂盒测定聚乙二醇化重组因子VIII（N8-GP）的FVIII活性：一项双中心研究。
Haemophilia. 2017 May;23(3):458-465. doi: 10.1111/hae.13168. Epub 2017 Feb 14.
4
The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.在常规临床实践中使用延长半衰期的凝血因子浓缩物：英国血液学标准委员会的指南
Haemophilia. 2016 Jul;22(4):487-98. doi: 10.1111/hae.13013. Epub 2016 Jun 16.
5
Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.由于硅介导的提前转化为激活的因子 IX，在一步法因子 IX 凝血测定中高估了 N-糖基化聚乙二醇化因子 IX 的活性。
J Thromb Haemost. 2016 Jul;14(7):1420-7. doi: 10.1111/jth.13359. Epub 2016 Jun 22.
6
A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.因子VIII Fc融合蛋白的单链变体在体内保留正常疗效，但在体外表现出改变的活性。
PLoS One. 2014 Nov 21;9(11):e113600. doi: 10.1371/journal.pone.0113600. eCollection 2014.
7
Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.比较性现场研究：实验室检测变异性对重组凝血因子IX Fc融合蛋白（rFIXFc）活性评估的影响
Thromb Haemost. 2014 Nov;112(5):932-40. doi: 10.1160/TH13-11-0971. Epub 2014 Aug 21.
8
Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.用于临床监测聚乙二醇化重组因子VIII（BAY 94-9027）治疗甲型血友病的活化部分凝血活酶时间测定法的评估。
Haemophilia. 2014 Jul;20(4):593-600. doi: 10.1111/hae.12374. Epub 2014 Jan 29.
Zotero 插件